Hematology/Oncology

Top Story

Trimodality therapy may reduce locoregional recurrence in inflammatory breast cancer

April 27, 2017

Locoregional recurrence appeared rare among patients with breast cancer treated with trimodality therapy, according to study results presented at the American Society of Breast Surgeons Annual Meeting.

Inflammatory breast cancer is an aggressive and rare disease; however, relatively small patient sampling has led to limited research in treatment.

FDA News

FDA expands approval of Stivarga to include liver cancer

April 27, 2017
The FDA expanded the approval of regorafenib to include the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib…
Meeting News

Contralateral breast cancer uncommon among women with ductal carcinoma in situ

April 27, 2017
Fewer than 6% of women with ductal carcinoma in situ developed contralateral breast cancer within 10 years, according to study results presented at the American Society…
In the Journals Plus

Incidence, prevalence of neuroendocrine tumors on the rise

April 27, 2017
Incidence and prevalence of neuroendocrine tumors are steadily rising, possibly due to better detection of early-stage disease and stage migration, according to a…
FDA News

FDA grants breakthrough therapy designation to lorlatinib for ALK–positive NSCLC

April 27, 2017
The FDA granted breakthrough therapy designation to lorlatinib for the treatment of patients with anaplastic lymphoma kinase–positive metastatic non–small…
More News Headlines »
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Video
Meeting News

VIDEO: Managing immune-related adverse events requires multidisciplinary approach

April 13, 2017
More »
Featured
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting

CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement